Cosunter(SZ:300436) Xin Lang Cai Jing·2025-09-12 09:04Group 1 - The core viewpoint of the news is that Guangshengtang has seen a significant increase in its stock price, rising by 5.01% to reach 119.76 yuan per share, with a trading volume of 1.188 billion yuan and a turnover rate of 7.52%, resulting in a total market capitalization of 19.074 billion yuan [1] - Guangshengtang Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its main business revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and was listed on April 22, 2015, located in Fuzhou, Fujian Province [1] Group 2 - Among the top ten circulating shareholders of Guangshengtang, a fund under China Europe Fund has increased its holdings by 393,100 shares, bringing its total to 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed Fund A (003095) has achieved a year-to-date return of 31.02% and a one-year return of 47.65%, ranking 2473 out of 8174 and 3246 out of 7981 respectively [2] - The fund manager, Ge Lan, has a tenure of 10 years and 230 days, with the fund's total asset size at 39.908 billion yuan and a best return of 128.86% during her tenure [3]